IFITM1: Interferon-Induced Transmembrane Protein 1
A key interferon-stimulated gene (ISG) involved in antiviral immunity, cell proliferation, and cancer progression.
Gene Information Card
| Symbol | IFITM1 |
|---|---|
| Full Name | Interferon Induced Transmembrane Protein 1 |
| Gene Type | Protein coding |
| Chromosomal Location | 11p15.5 |
| NCBI Gene ID | 8519 ncbi.nlm.nih.gov/gene/8519 |
| Ensembl ID | ENSG00000185885 |
| UniProt ID | P13164 |
| OMIM ID | 604456 |
| HGNC ID | 5412 |
| Aliases | CD225, IFI17, LEU13, 9-27 |
Description
IFITM1 (Interferon Induced Transmembrane Protein 1) is a member of the interferon-induced transmembrane protein family. It is encoded by a gene located on chromosome 11p15.5. The protein is a small transmembrane protein that localizes to the plasma membrane and endosomal compartments. IFITM1 is strongly induced by type I and type II interferons and plays a critical role in the innate immune response by restricting the entry of a broad range of enveloped viruses, including influenza A virus, dengue virus, and SARS-CoV-2. Beyond antiviral activity, IFITM1 is involved in cell proliferation, cell adhesion, and immune cell signaling. Dysregulation of IFITM1 expression has been implicated in various cancers, where it can act as either an oncogene or a tumor suppressor depending on the context.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Influenza A virus infection | IFITM1 blocks viral entry by inhibiting hemagglutinin-mediated membrane fusion | Experimental evidence: overexpression reduces viral titers in vitro (NCBI, UniProt) |
| Dengue virus infection | Restricts viral entry by interfering with endosomal fusion | Functional studies in cell lines (UniProt, PubMed) |
| SARS-CoV-2 infection | IFITM1 inhibits spike protein-mediated membrane fusion | In vitro assays and pseudovirus entry assays (NCBI, ClinVar) |
| Breast cancer | Overexpression associated with increased cell proliferation and poor prognosis | Expression profiling and clinical correlation studies (COSMIC, NCBI) |
| Colorectal cancer | Upregulation linked to tumor progression and metastasis | Immunohistochemistry and RNA-seq data (COSMIC, PubMed) |
| Gastric cancer | IFITM1 promotes cell migration and invasion | Functional assays in gastric cancer cell lines (NCBI, COSMIC) |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lung | 12.5 | Medium |
| Spleen | 18.3 | High |
| Lymph node | 15.7 | High |
| Bone marrow | 8.9 | Medium |
| Small intestine | 6.2 | Low |
| Liver | 3.1 | Low |
| Brain | 0.8 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| A549 (lung carcinoma) | 22.4 | High expression |
| HeLa (cervical carcinoma) | 15.1 | Medium expression |
| MCF7 (breast carcinoma) | 9.8 | Medium expression |
| HepG2 (hepatocellular carcinoma) | 4.2 | Low expression |
| K562 (leukemia) | 18.9 | High expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | Missense | <0.01% | Potential loss of start codon; functional impact unknown |
| c.100C>T (p.Arg34Trp) | Missense | <0.01% | Rare variant; no known disease association |
| c.200G>A (p.Gly67Glu) | Missense | <0.01% | Rare; predicted benign by in silico tools |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in ClinVar or COSMIC.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
| • plasma membrane (GO:0005886) | • integral component of membrane (GO:0016021) |
| • innate immune response (GO:0045087) | • fusion of virus membrane with host endosome membrane (GO:0039654) |
| • protein binding (GO:0005515) | • negative regulation of viral entry into host cell (GO:0046597) |
Pathways
• Interferon alpha/beta signaling (Reactome: R-HSA-909733)
• Antiviral mechanism by IFN-stimulated genes (Reactome: R-HSA-1169410)
• Innate Immune System (Reactome: R-HSA-168249)
Protein Summary
IFITM1 is a 125-amino acid transmembrane protein with two hydrophobic domains and a conserved intracellular loop. It is localized to the plasma membrane and endosomes. The protein inhibits viral entry by blocking membrane fusion, likely by altering membrane fluidity and curvature. IFITM1 also modulates cell proliferation and adhesion through interactions with CD81 and other tetraspanins. Post-translational modifications include palmitoylation and ubiquitination, which regulate its stability and antiviral activity.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IFITM10 Knockout HEK293 Cell Line | EDJ-KQ11675 | Human | 402778 | Details Get a Quote |
| IFITM1 Knockout HEK293 Cell Line | EDJ-KQ50795 | Human | 8519 | Details Get a Quote |
| IFITM1 Knockout HeLa Cell Line | EDJ-KQ54928 | Human | 8519 | Details Get a Quote |
| IFITM10 Knockout HeLa Cell Line | EDJ-KQ60329 | Human | 402778 | Details Get a Quote |
| IFITM1 Knockout A-549 Cell Line | EDJ-KQ63414 | Human | 8519 | Details Get a Quote |
| IFITM10 Knockout A-549 Cell Line | EDJ-KQ68796 | Human | 402778 | Details Get a Quote |
| IFITM1 Knockout HCT 116 Cell Line | EDJ-KQ71878 | Human | 8519 | Details Get a Quote |
| IFITM10 Knockout HCT 116 Cell Line | EDJ-KQ77159 | Human | 402778 | Details Get a Quote |
